🇺🇸 FDA
Patent

US 10406148

Methods of treatment using a JAK inhibitor compound

granted A61KA61K31/4545A61K9/0019

Quick answer

US patent 10406148 (Methods of treatment using a JAK inhibitor compound) held by Theravance Biopharma R&D IP, LLC expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/4545, A61K9/0019, A61K9/0048, A61K9/0075